Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice

BMC Cardiovascular Disorders

Fadhil G Al-amran¹  Nasser Ghaly Yousif² 

[1] Kufa University, Surgical Dept -College of Medicine, Najaf, Iraq;Asadder Teaching Hospital, Al-najaf, Iraq

关键词: trastuzumab;    Inflammation;    cardiac-toxicity;    Toll Like Receptor 4;   

Others  :  1085629
DOI  :  10.1186/1471-2261-11-62

 received in 2010-11-23, accepted in 2011-10-14,  发布年份 2011

【 摘 要 】

Background

Cardiac inflammation and generation of oxidative stress are known to contribute to trastuzumab (herceptin) induced cardiac toxicity. Toll-like receptors (TLRs) are a part of the innate immune system and are involved in cardiac stress reactions. Since TLR4 might play a relevant role in cardiac inflammatory signaling, we investigated whether or not TLR4 is involved in trastuzumab induced cardiotoxicity.

Methods

Seven days after a single injection of herceptin (2 mg/kg; i.p.), left ventricular pressure volume loops were measured in HeN compotent (TLR4^+/+) and HeJ mutant (TLR4^-/-) treated with trastuzumab and control mice. Immunofluorescent staining for monocyte infiltration and analyses of plasma by (ELISAs) for different chemokines including: MCP-1and tumor necrosis factor-α (TNF-α), Western immunoblotting assay for ICAM-1, and used troponin I for cardiac injury marker.

Results

Trastuzumab injection resulted in an impairment of left ventricular function in TLR-4 competent (HeN), in contrast TLR4^-/^- trastuzumab mice showed improved left ventricular function EF%, CO; p < 0.05, attenuation of mononuclear cell infiltration in TLR4 ^-/-; p < 0.05 vs.TLR-4 competent (HeN), reduced level of cytokines TNF-α, MCP-1 and ICAM-1 expression in TLR4^-/-, marked reduction of myocardial troponin-I levels in TLR4-deficient mice. Data are presented as means ± SE; n = 8 in each group p < 0.05 vs.TLR-4 competent (HeN).

Conclusions

Treatment with trastuzumab induces an inflammatory response that contributes to myocardial tissue TLR4 mediates chemokine expression (TNF-α, MCP-1and ICAM-1), so in experimental animals TLR4 deficiency improves left ventricular function and attenuates pathophysiological key mechanisms in trastuzumab induced cardiomyopathy.

【 授权许可】

   
2011 Yousif and Al-amran; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hudis CA: Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
• [2]Tripathy Debu: Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways. Nature Reviews Clinical Oncology 2007, (4):220-221.
• [3]Chien AJ, Rugo HS: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco. Expert Opin Drug Saf 2010, 9(2):335-346.
• [4]Seidman A, et al.: Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncology 2002, 20(5):1215-1221.
• [5]Garratt AN, Ozcelik C, Birchmeier C: ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 2003, 13:80-86.
• [6]Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
• [7]Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
• [8]Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al.: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide--evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
• [9]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
• [10]Kaczorowski DavidJ, Nakao Atsunori, Mollen KevinP, Vallabhaneni Raghuveer, Sugimoto Ryujiro, Kohmoto Junichi, Tobita Kimimasa, Zuckerbraun BrianS, McCurry KennethR, Murase Noriko, Billiar TimothyR: Toll-ike Receptor 4 Mediates the Early Inflammatory Response After Cold Ischemia/Reperfusion. Transplantation 2007, 84(10):1279-1287.
• [11]Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004, 109:784-789.
• [12]Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
• [13]Liu L, Zhang X, Qian B, Min X, Gao X, Li C, et al.: Over-expression of heat shock protein 27 atte nuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 2007.
• [14]Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
• [15]Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J: Expansion of circulating Toll-like receptor 4-positive monocytes in patients acute coronary syndrome. Circulation 2005, 111(20):2654-61.
• [16]Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
• [17]Junttila TT, Akita RW, Parsons K, et al.: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
• [18]Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
• [19]Katsumi Y, Kuwahara Y, Tamura S, et al.: Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin Cancer Res 2008, 14:1192-1199.
• [20]Musolino A, Naldi N, Bortesi B, et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
• [21]Bedard PL, Piccart-Gebhart MJ: Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008, 8(suppl 4):S157-165.
• [22]Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98.
• [23]De Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M: Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009, 4:77-88.
• [24]Shames BD, Barton HH, Reznikov LL, Cairns CB, Banerjee A, Harken AH, Meng X: Ischemia alone is sufficient to induce TNF- mRNA and peptide in the myocardium. Shock 2002, 17:114-119.
• [25]Cha J, Wang Z, Ao L, Zou N, Dinarello CA, Banerjee A, Fullerton DA, Meng X: Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 2008, 85:1678-1685.
• [26]Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED: Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004, 128:170-179.
• [27]Cha John, Wang Zhiping, Ao Lihua, Zou Ning, Dinarello CharlesA, Banerjee Anirban, Fullerton DavidA, Meng Xianzhong: Cytokines Link Toll-Like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 2008, 85:1678-85.
• [28]Kaczorowski DavidJ, Nakao Atsunori, Mollen KevinP, Vallabhaneni Raghuveer, Sugimoto Ryujiro, Kohmoto Junichi, Tobita Kimimasa, Zuckerbraun BrianS, McCurry KennethR, Murase Noriko, Billiar TimothyR: Toll-like Receptor 4 Mediates the Early Inflammatory Response After Cold Ischemia/Reperfusion. Transplantation 2007, 84(10):1279-1287.
• [29]Yousif NG, Ao L, Li J, Aly A, Austin E, Fullerton DA, Meng X: Myocardial Tissue TLR4 Plays a Major Role in Mediating Myocardial Injury Following Cold Ischemia and Reperfusion Through Up-regulation Of MCP-1. ASC 2011 Abstract, Quick shot, Transplant & Immunology (Transplant/Immunology)
• [30]Al-amran FG, Yousif NG, Meng XM: A TLR4-MCP-1-macrophage IL-18 Cascade plays major role in Myocardial Injury and Cardiac Dysfunction after Permanent Ischemia. 6th Annual Academic Surgical Congress 2011 Abstract, schemia & Cardiopulmonary By. pass (Cardiothoracic)